Literature DB >> 2138210

Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody.

J J Schlesinger1, M W Brandriss, J R Putnak, E E Walsh.   

Abstract

Among antibodies to flaviviral proteins only those directed at the virion envelope protein (E) or the non-structural glycoprotein NS1 are known to confer protection. To investigate the possible role of complement-mediated cytolysis (CMC) in protection we measured the capacity of anti-NS1, or E monospecific serum or monoclonal antibodies to bind to yellow fever virus (YFV)-infected cells and of anti-NS1 or E serum to sensitize them to CMC. Although both anti-NS1 and anti-E antibody bound to YFV-infected cells, CMC was observed only with anti-NS1 antibody. Greater binding by anti-NS1 antibody suggested the presence of larger amounts of NS1 than E associated with the cell membrane. Using the cell membrane-impermeable, cross-linking reagent BS3, cell surface NS1, but not E, was detected as a homopolymer, a form in which bound antibody might be expected to activate complement more efficiently. Peak titres of progeny virus were reduced 10- to 100-fold when infected cells were treated with complement-fixing, anti-NS1 monoclonal antibody or monospecific, anti-NS1 rabbit serum and complement. Taken together these results are consistent with the hypothesis that CMC subserved by anti-NS1 antibody provides an alternative to direct neutralization of virus in the protective immune response to flaviviral infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138210     DOI: 10.1099/0022-1317-71-3-593

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  27 in total

1.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

2.  Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum.

Authors:  Melissa C Whiteman; Vsevolod Popov; Michael B Sherman; Julie Wen; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections.

Authors:  Sophie Alcon; Antoine Talarmin; Monique Debruyne; Andrew Falconar; Vincent Deubel; Marie Flamand
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion.

Authors:  M Flamand; F Megret; M Mathieu; J Lepault; F A Rey; V Deubel
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Flow cytometry compared with indirect immunofluorescence for rapid detection of dengue virus type 1 after amplification in tissue culture.

Authors:  C L Kao; M C Wu; Y H Chiu; J L Lin; Y C Wu; Y Y Yueh; L K Chen; M F Shaio; C C King
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

6.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model.

Authors:  S C Jacobs; J R Stephenson; G W Wilkinson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells.

Authors:  Venkatramana D Krishna; Manjuladevi Rangappa; Vijaya Satchidanandam
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

Review 9.  Oligomeric viral proteins: small in size, large in presence.

Authors:  Bhargavi Jayaraman; Amber M Smith; Jason D Fernandes; Alan D Frankel
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-08-14       Impact factor: 8.250

Review 10.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.